Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy-Reference-Cited by-同舟云学术

Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

Published:2014-01-30 Issue:1 Volume:9 Page:
ISSN:1748-717X
Container-title:Radiation Oncology
language:en
Short-container-title:Radiat Oncol

Author:

Horne Zachary D,Clump David A,Vargo John A,Shah Samir,Beriwal Sushil,Burton Steven A,Quinn Annette E,Schuchert Matthew J,Landreneau Rodney J,Christie Neil A,Luketich James D,Heron Dwight E

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,Oncology

Link

https://link.springer.com/content/pdf/10.1186/1748-717X-9-41.pdf

Reference23 articles.

1. Kligerman S, Digumarthy S: Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol 2009,193(5):1203-1211. 10.2214/AJR.09.3193

2. Mac Manus MP, Hicks RJ: The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Semin Nucl Med 2012,42(5):308-319. 10.1053/j.semnuclmed.2012.04.003

3. Paesmans M, Berghmans T, Dusart M, et al.: Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol: Offic Publ Int Assoc Stud Lung Canc 2010,5(5):612-619.

4. Onishi H, Shirato H, Nagata Y, et al.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol: Offic Publ Int Assoc Stud Lung Canc 2007,2(7 Suppl 3):S94-S100.

5. Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA: J Am Med Assoc 2010,303(11):1070-1076. 10.1001/jama.2010.261

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiomic phenotypes of the background lung parenchyma from [18]F-FDG PET/CT images can augment tumor radiomics and clinical factors in predicting response after surgical resection of tumors in patients with non-small cell lung cancer;Medical Imaging 2024: Computer-Aided Diagnosis;2024-04-03

2. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation;Radiotherapy and Oncology;2024-01

3. Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy;Advances in Radiation Oncology;2024-01

4. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model;Journal of Thoracic Oncology;2023-03

5. Necrosis on pre-radiotherapy 18F-FDG PET/CT is a predictor for complete metabolic response in patients with non-small cell lung cancer;Medicine;2022-05-20